Sivers Semiconductors AB (SIVEF) — US OTC Line · Investment Tree v1
🔁 MIRROR CARD — same equity as SIVE. SIVEF is the US OTC line (USD) of Sivers Semiconductors AB; SIVE.ST on Nasdaq Stockholm (SEK) is the primary, liquid listing. They are the same shares, same thesis, same verdict — only the venue and currency differ. To avoid two copies drifting apart, the full maintained dossier lives under
reports/SIVE/(all 20 artifacts: tree, durability test, scenarios, evidence JSONL, glossary, etc.). This card carries the identical INDEX_META so it renders correctly under either symbol, plus the verdict, snapshot, and the OTC-line-specific mechanics. For the complete analysis (the MECE tree, valuation regimes, durability test, triggers, and the 15-question scorecard), read SIVE → tree_v1_en.md.
🔴 SPECULATIVE / FRAGILE-THESIS — DEFAULT VERDICT: AVOID (not a 5-10 year hold). A pre-profit, cash-burning ~$32M-revenue Swedish photonics small-cap whose stock is up ~1,800% YTD on an AI-photonics narrative, now carrying a live Swedish insider-trading/market-abuse probe (Ekobrottsmyndigheten + Finansinspektionen, over a leak ~48h before the April 2026 US-listing announcement), a restatement that CUT revenue and WIDENED losses, a credible short report (Ningi, 2026-06-01) alleging ~31% of FY2025 revenue is dubious, US securities class-action investigations (Rosen, Bronstein), and insiders + a directed-issue fund selling their ENTIRE stakes into the rally. Durability 8/25 with 3 fatal flags = UNOWNABLE for a long-term hold.
Mirror of reports/SIVE/tree_v1_en.md. Bilingual companion: tree_v1_zh.md. Date: 2026-06-08 · Anchor (this card): SIVEF $7.77 (US OTC, 2026-06-05) ≈ SIVE.ST SEK 78.80 at SEK/USD ~9.42 · ATH SEK 110 on 2026-06-03 · Market cap ~SEK 23–25bn / ~$2.5–2.7bn · ~295–320M shares (count disputed) · Cash YE2025 SEK 43.5M; Q1 burn ~SEK 49M/qtr · Dividend: none
0. Why this card exists (and which symbol to actually trade)
Ming can see Sivers under two tickers, so both render a card; this one (SIVEF) is a mirror so the analysis surfaces whichever symbol he searches. The substance is in SIVE.
Practical guidance specific to the SIVEF line:
| Attribute | SIVEF (US OTC) | SIVE.ST (Nasdaq Stockholm) |
|---|---|---|
| Currency | USD | SEK |
| Status | Unsponsored OTC ordinary line (≈1:1 to the common share; not a sponsored ADR — no sponsor bank, no DR program services) | Primary, exchange-listed common |
| Liquidity | Thin and stale — prints lag the Stockholm tape; the implied SIVEF/SEK cross (~10.1) sat below the spot FX (~9.42) at the 2026-06-05 anchor, i.e. the OTC line was pricing the shares ~7% cheap purely on staleness, not on a real arbitrage | Deep — was the single most-traded stock on the exchange during the Ningi sell-off (turnover ~SEK 560M, > Saab) |
| Spread / execution | Wide; fills unreliable for any size | Tight |
| Dividend / withholding | None paid → Swedish 30% dividend withholding is moot today | Same |
| Recommendation | If (against this verdict) one ever transacts, use the SEK primary — not this OTC line. SIVEF adds liquidity, staleness, and price-discovery risk on top of an already-AVOID name. | The correct venue |
This OTC line also adds liquidity risk and price-discovery risk to the seven other risk types catalogued for SIVE — making the AVOID conclusion, if anything, stronger for the SIVEF buyer than the SIVE.ST buyer.
I. One-sentence verdict
Sivers is a genuine InP-laser foundry with a real (but narrow) efficiency edge and two real (but non-binding) AI-optics partnerships — wrapped in a ~$32M-revenue, perpetually-loss-making, serially-diluting shell that has been bid up ~1,800% YTD into a ~$2.7bn / ~80x-sales valuation, and is now simultaneously fighting a live insider-trading probe, a revenue-cutting restatement, a credible 31%-dubious-revenue short report, US class-action investigations, and visible insider exit-selling; with durability 8/25 (3 fatal flags) and an expected value of roughly −47%, the only defensible action for a 5-10 year holder is AVOID — the asymmetry runs against the long, and the credible trade is the short. (Buying the SIVEF OTC line instead of the SEK primary only adds liquidity and staleness risk.)
II. Company snapshot
Sivers Semiconductors AB (publ) is a Swedish photonics + RF semiconductor company (HQ Kista; roots to 1951) in two segments: Photonics (Sivers Photonics, the Glasgow III-V/InP foundry from the 2017 CST Global acquisition — InP DFB lasers, gain chips, PICs, silicon-photonics enablement; the AI-datacenter CPO/LPO/LRO + LiDAR + SATCOM story) and Wireless (Sivers Wireless incl. 2022 MixComm — fabless RF/mmWave beamforming ICs; 5G/FWA/SATCOM). Primary listing Nasdaq Stockholm (SIVE.ST, SEK); US OTC ordinary (SIVEF, USD — this card).
Pre-profit and cash-burning. Restated FY2025 (published ~2026-05-15 after a PCAOB audit uplift for a potential US dual listing): net sales SEK 306.6M (~$32M), EBIT SEK -177.8M, net loss SEK -222.6M — the restatement CUT revenue and WIDENED losses vs the original figures. Cash at YE2025 was SEK 43.5M against Q1 2026 operating burn of SEK -49.2M — one quarter of burn exceeded the entire cash balance. Q1 2026 net sales SEK 61.9M (-22% YoY) on US government-shutdown / defense-budget delays and FX. The momentum bid frames SIVE as an InP-laser "chokepoint" for the AI-optics supercycle, validated by GlobalFoundries (2026-06-02) and Jabil (OFC 2026) partnerships and a $799M "opportunity pipeline" (+77% YTD); the credible short case (Ningi; short interest 1.6%→17%) calls it "a retail-driven pump built on speculative hyperscaler relationships, a fabricated bottleneck narrative, a rumored volume ramp-up, a delayed US listing, and a vague opportunity pipeline."
III.–X. Full analysis → see SIVE
The MECE tree (H-0 + branches: AI-optics conversion, Wireless/SATCOM, financing/runway/dilution, moat/IP, competitive design-out, integrity overhang), the valuation regimes, the long-term durability test, the triggers & red flags with the 应对 playbook, and the falsification analysis are maintained in one place to prevent drift:
➡️ reports/SIVE/tree_v1_en.md (English) · tree_v1_zh.md (中文) Supporting artifacts: reports/SIVE/durability_test.md, scenarios.md, triggers_redflags.md, evidence_2026-06-08.jsonl, glossary.md, peers.md, and the rest of the 20-file dossier.
Headline numbers carried from that analysis: verdict tally 1 ✅ · 8 ⚠️ · 8 ✗ · 3 ⊗; H-0 confidence ~28% (leaning falsified); scenario probability Bull 15 / Base 50 / Bear 35; expected value ~−47%; durability 8/25 with 3 fatal flags; XII weighted score 22%.
XI. Position conclusion (verdict for Ming)
AVOID — for both the SIVE.ST and SIVEF lines; if anything the OTC line is worse.
- ❌ Do NOT buy / do NOT initiate. Durability 8/25, 3 fatal flags, EV ~−47%, live insider-trading probe, ~80x sales.
- ❌ Do NOT average down if legacy-held — treat as a written-off option; exit into strength.
- ❌ Do NOT use SIVEF to "get cheap entry." The ~7% staleness discount to the SEK tape is an illiquidity artifact, not value; you may be unable to exit at the quoted price.
- 📅 Re-engage only if a real committed volume PO AND a clean US listing with the probe closed BOTH fire, at a far lower multiple.
- 📅 Watch the June 15 AGM (board + 53.8M-share dilution authorization) and the ~Aug Q2 interim (revenue recovery? any volume PO?).
- ✅ If the InP-optics THEME is wanted, own scaled, profitable names (Lumentum, Coherent, MACOM) instead.
XII. Investment Scorecard → see SIVE
The full 15-question long-term-hold scorecard, the K.3.5 4-tier weighted-score derivation (22%), the scorecard summary, the 2-minute pitch, the relevant risk types, and the "When NOT to buy" anti-pattern check (every major anti-pattern fires — retail hype, parabolic move, AI-attached, story-over-numbers, plus integrity tells) are in SIVE → §XII.
Bottom line: this is the canonical configuration the discipline is built to refuse. AVOID. Buying it through the illiquid SIVEF OTC line rather than the SEK primary only compounds the reasons not to.
Mirror card written 2026-06-08. Canonical source of truth: reports/SIVE/. Next refresh tracks SIVE: ~Aug 2026 (Q2 interim) + June 15 AGM outcome, or immediately on any integrity escalation (insider-trading charges, restatement #2, US listing blocked). When SIVE updates, re-sync this card's INDEX_META + verdict.